Praxis Precision Medicines Inc (PRAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Praxis Precision Medicines Inc (PRAX) has a cash flow conversion efficiency ratio of -0.058x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-77.64 Million) by net assets ($1.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PRAX stock market capitalisation for the company's overall valuation and market capitalisation.
Praxis Precision Medicines Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Praxis Precision Medicines Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Praxis Precision Medicines Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Praxis Precision Medicines Inc ranked by their cash flow conversion efficiency. See PRAX cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pharmaron Beijing Co Ltd
SHE:300759
|
0.068x |
|
Dr. Reddy's Laboratories Limited
F:RDDA
|
0.029x |
|
Universal Health Services Inc
NYSE:UHS
|
0.053x |
|
DEUTSCHE WOHNEN ADRS/1/2
F:DWNP
|
0.029x |
|
Pentair plc
STU:PNT
|
0.153x |
|
AVIC Aircraft Co Ltd
SHE:000768
|
0.164x |
|
Hyundai Rotem Co
KO:064350
|
0.677x |
|
Inner Mongolia Xingye Mining Co Ltd
SHE:000426
|
0.095x |
Annual Cash Flow Conversion Efficiency for Praxis Precision Medicines Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Praxis Precision Medicines Inc from 2018 to 2025. View Praxis Precision Medicines Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $878.14 Million | $-249.07 Million | -0.284x | +4.11% |
| 2024-12-31 | $445.45 Million | $-131.76 Million | -0.296x | +81.46% |
| 2023-12-31 | $69.67 Million | $-111.14 Million | -1.595x | +34.39% |
| 2022-12-31 | $76.11 Million | $-185.04 Million | -2.431x | -389.60% |
| 2021-12-31 | $250.81 Million | $-124.55 Million | -0.497x | -171.27% |
| 2020-12-31 | $287.46 Million | $-52.62 Million | -0.183x | +77.60% |
| 2019-12-31 | $40.11 Million | $-32.79 Million | -0.817x | +42.09% |
| 2018-12-31 | $14.68 Million | $-20.72 Million | -1.411x | -- |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more